Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10073
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNilupul Perera, Men
dc.contributor.authorMa, Henry Ken
dc.contributor.authorArakawa, Shujien
dc.contributor.authorHowells, David Williamen
dc.contributor.authorMarkus, Romeshen
dc.contributor.authorRowe, Christopher Cen
dc.contributor.authorDonnan, Geoffrey Aen
dc.date.accessioned2015-05-15T23:24:40Z
dc.date.available2015-05-15T23:24:40Z
dc.date.issued2006-01-01en
dc.identifier.citationJournal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia; 13(1): 1-8en
dc.identifier.govdoc16410192en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10073en
dc.description.abstractStroke is one of the leading causes of mortality and morbidity. The stroke process triggers an inflammatory reaction that may last up to several months. Suppression of inflammation using a variety of drugs reduces infarct volume and improves clinical outcomes in animal models of stroke. This benefit occurs even with the initiation of therapy after 3 hours of onset of stroke, beyond the therapeutic window for thrombolysis with tPA. The use of neuroprotectants to suppress inflammation may widen the therapeutic time window for tPA while lessening its side-effects. Suppression of inflammation may also improve outcomes in animal models of haemorrhagic stroke. To date, clinical trials with anti-inflammatory agents in acute ischaemic stroke have failed to improve clinical outcomes. However, because of the potential for broader applicability across all aspects of stroke, a better understanding of anti-inflammatory mechanisms is important.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherDisease Models, Animalen
dc.subject.otherFibrinolytic Agents.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherInflammation.etiology.prevention & controlen
dc.subject.otherStroke.complications.therapyen
dc.subject.otherTime Factorsen
dc.subject.otherTissue Plasminogen Activator.therapeutic useen
dc.titleInflammation following stroke.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Clinical Neuroscienceen
dc.identifier.affiliationNational Stroke Research Institute, Austin Health, University of Melbourne, Level 1, Neurosciences Building, 300 Waterdale Road, Heidelberg Heights, Victoria 3081, Australiaen
dc.identifier.doi10.1016/j.jocn.2005.07.005en
dc.description.pages1-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16410192en
dc.type.austinJournal Articleen
local.name.researcherDonnan, Geoffrey A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

200
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.